Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor

NCT07768189 is registered in ClinicalTrials.gov with Corbus Pharmaceuticals Inc. as lead sponsor.

NCT NCT07768189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07768189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor
Lead sponsor
Corbus Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
September 29, 2026
Completion date
March 31, 2029
Enrollment
260 (estimated)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal carcinoma (opc)